ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) will be issuing its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of $1.09 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.38-4.82 EPS and its FY 2024 guidance at 4.380-4.820 EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business's revenue for the quarter was up 18.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.06 earnings per share. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Trading Up 1.7 %

NASDAQ:ANIP traded up $0.95 on Friday, reaching $58.19. The stock had a trading volume of 241,051 shares, compared to its average volume of 211,124. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 49.74 and a beta of 0.71. The firm's fifty day moving average is $59.20 and its two-hundred day moving average is $61.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ANIP shares. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 22nd. Raymond James lifted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Finally, Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.